Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 10;11(12):3342.
doi: 10.3390/jcm11123342.

Novel Drugs in a Pipeline for Progressive Multiple Sclerosis

Klaudia Sapko  1 , Anna Jamroz-Wiśniewska  1 , Konrad Rejdak  1
Affiliations
Review

Novel Drugs in a Pipeline for Progressive Multiple Sclerosis

Klaudia Sapko et al. J Clin Med. .

Abstract

Multiple sclerosis (MS) is a widely known inflammatory, demyelinating disease of the central nervous system. The pathogenesis of progressive multiple sclerosis (PMS) is a complex, multi-level process that causes therapeutic difficulties. Along with variables such as age and duration of the disease, pathogenetic mechanisms change from inflammatory to neurodegenerative processes. Therefore, the efficacy of available anti-inflammatory drugs approved for the treatment of PMS, such as ocrelizumab or siponimod, is limited in time. In search of innovative solutions, several research studies have been conducted to evaluate the effectiveness of drugs with neuroprotective or remyelinating effects in PMS, including biotin, ibudilast, simvastatin, alpha-lipoic acid, clemastine, amiloride, fluoxetine, riluzole, masitinib, opicinumab, and lamotrigine. The current review includes those compounds, which have entered the clinical phase of assessment, and the authors discuss future prospects for successful PMS treatment.

Keywords: clinical trials; multiple sclerosis; neuroprotective drugs; progressive multiple sclerosis; remyelinating drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brownlee W.J., Hardy T.A., Fazekas F., Miller D.H. Diagnosis of multiple sclerosis: Progress and challenges. Lancet. 2017;389:1336–1346. doi: 10.1016/S0140-6736(16)30959-X. - DOI - PubMed
    1. Rejdak K., Jackson S., Giovannoni G. Multiple sclerosis: A practical overview for clinicians. Br. Med. Bull. 2010;95:79–104. doi: 10.1093/bmb/ldq017. - DOI - PubMed
    1. Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S., Thompson A.J., Wolinsky J.S., Balcer L.J., Banwell B., Barkhof F., et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. - DOI - PMC - PubMed
    1. Mahad D.H., Trapp B.D., Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–193. doi: 10.1016/S1474-4422(14)70256-X. - DOI - PubMed
    1. Correale J., Gaitán M.I., Ysrraelit M.C., Fiol M.P. Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain. 2017;140:527–546. doi: 10.1093/brain/aww258. - DOI - PubMed

LinkOut - more resources